Digg
Del.icio.us
Newsvine 
Facebook
Stumbleupon
CHOLESTEROL COUNT: Three studies of the cholesterol-lowering drug Vytorin, funded by its makers, can't prove or rule out a possible link to a higher risk of cancer that emerged this summer.
EXPERT OPINION: Top editors of the New England Journal of Medicine are urging doctors and patients to use caution and stick with statins if they work well enough. Vytorin contains a now-generic statin, Zocor, and a cholesterol drug that works differently, Zetia.
PHARMACEUTICAL FALLOUT: The findings could hurt sales of pricey Vytorin, plus share of makers Merck & Co. and Schering-Plough Corp.
At first I was going to post this story from the UK Telegraph as an interesting piece... food for thought if you will... with the tag that this t...
Online distributor for point of sale equipment, TYSSO and Pegasus.
Partners 
|
© 2009 The Ibtimes Company. All Rights Reserved. Terms of service | Privacy Policy | Advertising | About Us | Contact Us | Archives
EMAIL
PRINT
RSS
SHARE
-0.12
